ReviewCanadian journal of gastroenterology & hepatology2017
Metabonomics Research Progress on Liver Diseases.
Review in Canadian journal of gastroenterology & hepatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Trial
- Metabolomic Profiling of Hepatitis B-Associated Liver Disease Progression: Chronic Hepatitis B, Cirrhosis, and Hepatocellular Carcinoma.Metabolites · 2025Article
- Spatial metabolomics in mental disorders and traditional Chinese medicine: a review.Frontiers in pharmacology · 2025Review
- Altered urinary tryptophan metabolites in alcohol-associated liver disease.Alcohol, clinical & experimental research · 2023Article
- Metabolomics analysis of urine from patients with alcohol-associated liver disease reveals dysregulated caffeine metabolism.American journal of physiology. Gastrointestinal and liver physiology · 2023Article
- Exploring the mechanism of anti-chronic heart failure effect of qiweiqiangxin І granules based on metabolomics.Frontiers in pharmacology · 2023Article
- The role of hepatic microenvironment in hepatic fibrosis development.Annals of medicine · 2022Review
- Postbiotics Prepared UsingInternational journal of molecular sciences · 2022Article
- Respiratory Depression as Antibacterial Mechanism of Linalool againstInternational journal of molecular sciences · 2022Article
- The Potential Role of Metabolomics in Drug-Induced Liver Injury (DILI) Assessment.Metabolites · 2022Review
- Fraxinellone Induces Hepatotoxicity in Zebrafish through Oxidative Stress and the Transporters Pathway.Molecules (Basel, Switzerland) · 2022Article
- Metabolomic serum abnormalities in dogs with hepatopathies.Scientific reports · 2022Article
- Serum Metabolomics Analysis for Biomarkers ofFoods (Basel, Switzerland) · 2022Article
- Vitamin B6 Metabolic Pathway is Involved in the Pathogenesis of Liver Diseases via Multi-Omics Analysis.Journal of hepatocellular carcinoma · 2022Article
- Plasma metabolomic and lipidomic alterations associated with anti-tuberculosis drug-induced liver injury.Frontiers in pharmacology · 2022Article
- Urine metabolomics and microbiome analyses reveal the mechanism of anti-tuberculosis drug-induced liver injury, as assessed for causality using the updated RUCAM: A prospective study.Frontiers in immunology · 2022Article
- Non-uniformity of Changes in Drug-Metabolizing Enzymes and Transporters in Liver Cirrhosis: Implications for Drug Dosage Adjustment.Molecular pharmaceutics · 2021Article
- Plasma and stool metabolomics to identify microbiota derived-biomarkers of metabolic dysfunction-associated fatty liver disease: effect of PNPLA3 genotype.Metabolomics : Official journal of the Metabolomic Society · 2021Article
- Article
- Novel approaches to liver disease diagnosis and modeling.Translational gastroenterology and hepatology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolomics as the new omics technique develops after genomics, transcriptomics, and proteomics and has rapid development at present. Liver diseases are worldwide public health problems. In China, chronic hepatitis B and its secondary diseases are the common liver diseases. They can be diagnosed by the combination of history, virology, liver function, and medical imaging. However, some patients seldom have relevant physical examination, so the diagnosis may be delayed. Many other liver diseases, such as drug-induced liver injury (DILI), alcoholic liver disease (ALD) and nonalcoholic fatty liver disease (NAFLD), and autoimmune liver diseases, still do not have definite diagnostic markers; the diagnosis consists of history, medical imaging, and the relevant score. As a result, the clinical work becomes very complex. So it has broad prospects to explore the specific and sensitive biomarkers of liver diseases with metabolomics. In this paper, there are several summaries which are related to the current research progress and application of metabolomics on biomarkers of liver diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.